Ionizing radiation is an important component of multimodal therapy for alveolar rhabdomyosarcoma (ARMS). We sought to evaluate the ability of IFN-β to enhance the activity of ionizing radiation.
Introduction
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood, accounting for more than half of all soft tissue sarcomas in this patient population (1, 2) . The use of multimodal therapy has resulted in substantial improvement in cure rates for patients with rhabdomyosarcoma over the past 30 years. However, particular subsets of rhabdomyosarcoma still provide significant clinical challenges. Outcomes for patients with alveolar histology rhabdomyosarcoma (ARMS), for example, continue to lag behind those for embryonal histology, with Intergroup Rhabdomyosarcoma Study-IV results indicating that 5-year failure free survival for ARMS is only 65% despite intensive therapy (3, 4) .
Ionizing radiation is an integral part of multimodal therapy for rhabdomyosarcoma, especially ARMS. Radiotherapy can be used to shrink tumors before operative resection and is used to reduce recurrence by treating residual disease. Unfortunately, as with most treatments, ionizing radiation also produces dose-related side effects to surrounding normal tissue. Radiation therapy can be associated with complications, such as bone growth abnormalities, peripheral nerve injury, impaired mobility, and secondary malignancies (5) . The frequency of significant late effects of radiotherapy can be as high as 80% (5) . Adjuvant agents that augment the response of tumors to radiation might allow for the use of lower doses of ionizing radiation, thereby maintaining efficacy while decreasing toxicity.
One promising adjuvant agent is IFN-β. IFN-β inhibits tumor growth through diverse mechanisms of action including direct tumor cell toxicity (6) , upregulation of apoptosis (7) , and inhibition of angiogenesis (8) (9) (10) . Recently, we have shown that continuous delivery of IFN-β affects tumor angiogenesis by "normalizing" the dysfunctional tumor vasculature, decreasing vessel permeability and interstitial fluid pressure, and improving intratumoral blood flow. This, in turn, improves tumor oxygenation (11) .
Although the benefit of improving the perfusion and oxygenation of tumors may seem counterintuitive, tumor oxygenation has an important impact on the effectiveness of ionizing radiation (12) . Ionizing radiation kills tumor cells through the generation of oxygen free radicals, which cause DNA injury leading to apoptosis. Hypoxia has been shown to interfere with the cytotoxic effects of ionizing radiation as well as contribute to the emergence of radiation-resistant tumor cells (13, 14) . Achieving the same level of tumor cell killing requires three times the radiation dose under hypoxic conditions compared with normal states (12) . Hyperbaric oxygen (15) , erythropoietin (16) , alterations in hemoglobin affinity for oxygen (17) , and blood transfusions (18) are therapies that have been tried to improve intratumoral oxygenation and thereby improve tumor response to radiation. These approaches have had mixed results, however. This may be because each of these therapies changes the oxygen content within the blood, but if blood is not being delivered efficiently throughout a tumor, the effect of the interventions will be minimized.
Tumor angiogenesis results in an uneven distribution of blood vessels and perfusion throughout a tumor. Some areas of a tumor then become necrotic and hypoxic providing pockets of resistance to radiation therapy. The poor vessel quality inherently produced by tumor angiogenesis also results in leaky vessels, which increase the intratumoral interstitial pressure, compressing small vessels and further reducing perfusion throughout the tumor. Because ionizing radiation kills tumor cells through the creation of oxygen free radicals, increased perfusion and oxygenation of tumors should increase cell death in response to radiation therapy. Based on our prior experience, continuous delivery of IFN-β may produce this desired effect (11) . In addition, IFN-β has been shown to enhance the efficacy of radiation on several tumor cell lines in vitro through a direct effect (19) . Importantly, in that same study, IFN-β did not seem to increase the toxicity of radiation on nonmalignant cells (19) . We, therefore, hypothesized that treating alveolar rhabdomyosarcoma xenografts with IFN-β before radiation would result in greater antitumor response to radiation.
Materials and Methods

In vitro Analysis
Rh-30 and Rh-41 cell lines were provided by Dr. P. Houghton (St. Jude Children's Research Hospital). These cell lines had retained the histologic appearance of alveolar rhabdomyosarcoma and were tested by short tandem repeat analysis when initially derived (20) . Sensitivity to IFN-β was established using an MTS assay (CellTiter 96 AQueous One Solution, Promega). Cells were treated for a total of 96 h with 10 to 10,000 units of recombinant human IFN-β (Avonex, Biogen Idec, Inc.) given daily. All measurements were done with 12 replicates. To analyze the effects of IFN-β on cell cycle and apoptosis in these lines, cells were treated with 10 to 10,000 units of recombinant human IFN-β daily for 72 h, after which time cells were analyzed by flow cytometry for DNA content and Annexin V staining. All measurements were done in triplicate.
For in vitro radiosensitization studies, cells were treated with recombinant human IFN-β (Avonex) at concentrations of 30 to 3,000 IU/mL and incubated for 24 h before irradiation, as described by Schmidberger et al. (19) . Cells were irradiated with a cesium-137 source at single doses of 0, 1, 2, or 4 Gy. Media were changed in all flasks following irradiation to discontinue the exposure to IFN-β.
A standard colony-forming assay was used to assess cell survival. All treatment groups with varying combinations (4 × 5 factorial design) of radiation and IFN-β doses were maintained in culture for 10 d following treatment. Cells were fixed with methanol and stained with Giemsa (Sigma-Aldrich). Twenty dose combinations of IFN-β and radiation were evaluated, and each experiment was done with six replicates. An individual surviving colony was scored if >50 cells were present.
Adeno-Associated Virus Vector Production
Adeno-associated virus vectors (AAV) were used to establish continuous, long-term delivery of human IFN-β in vivo. Construction of the pAV2 hIFN-β and pAV2 FIX (human clotting factor IX) vector plasmids has been described previously (21) . AAV-FIX served as a control vector. These vector plasmids include the CMV-IE enhancer, β-actin promoter, a chicken β-actin/rabbit β-globin composite intron, and a rabbit β-globin polyadenylation signal mediating the expression of the cDNA for human IFN-β. The hIFN-β cDNA was purchased from InvivoGen. Recombinant AAV vectors pseudotyped with serotype 8 capsid were generated by the method described previously using the pAAV8-2 plasmid provided by J. Wilson (22) . These AAV2/8 vectors were purified using ion exchange chromatography (23) .
Murine Tumor Model
Orthotopic (IM) ARMS xenografts were established in male CB17 severe combined immunodeficient mice (Charles River Laboratory) by injection of 2 × 10 6 Rh-30 or Rh-41 tumor cells in 200 μL PBS into the right calf muscle during the administration of 2% isoflurane. The size of the IM tumors was estimated by measuring the size of the normal left calf and subtracting that volume from the tumor-injected right calf volume. Measurements were done weekly in two dimensions using handheld calipers, and volumes calculated as width 2 
Tumor Interstitial Fluid Pressure
Interstitial fluid pressure was measured in the tumors of sedated mice using a needle-pressure technique, which has previously been described (24) . The width of each tumor was measured, and a 23-gauge hollow bore needle was inserted into the tumor to a depth equal to one-third of the width, ensuring placement well within the tumor, but not directly in the potentially necrotic tumor center. Data are reported in cm H 2 O (1 cm H 2 O = 1.36 mm Hg).
Contrast-Enhanced Ultrasonography
Definity ultrasound contrast agent (Bristol-Myers Squibb) was used to perform contrast-enhanced ultrasonography on a Vevo 770 (Visual Sonics, Toronto, Ontario) small animal ultrasound machine using a 40-MHz linear transducer. Definity is a suspension of perflutren lipid microspheres designed for clinical use in echocardiography. Mean microsphere size ranges from 1.1 to 3.3 μm, and particles remain in the intravascular space. Ultrasound images were obtained while the mouse was sedated with 2% isoflurane with body temperature being maintained by a heat lamp and heated ultrasound platform. The ultrasound transducer was centered over the largest tumor area and held in that position throughout image acquisition. One hundred microliters of Definity mixed 1:1 with sterile PBS was injected into the venous system by retro-orbital injection. Imaging was recorded on a cine-clip beginning immediately before the contrast injection and continued for 60 s at a frame rate of 14 to 18 Hz. A region of interest was drawn to encompass the entire tumor, and the cine clip was evaluated for change in tumor signal intensity from pre-contrast-enhanced baseline to initial peak enhancement (ΔSI in decibels, dB).
In vivo Oxygen Tension Measurement
Tumor oxygen tension levels were measured in vivo using the OxyLab fiber optic probe (Oxford Optronics). The OxyLab system probe is coated in ruthenium pigment, which is excited by the fiber optic blue light. Oxygen quenches the excitation providing a calculation of the oxygen pressure in mm Hg. Mice were anesthetized with ketamine mixed with xylazine and normal saline. While sedated, the mice were placed on two liters of continuous flow oxygen by nose cone. A 23-gauge needle was inserted across the diameter of the tumor at its midpoint.
The needle was then withdrawn ∼5 mm, and the probe was inserted through the lumen of the needle. Oxygen pressure was measured at 5-min intervals for 25 min, and a steady-state level was recorded.
Tumor Immunohistochemistry
Formalin-fixed, paraffin-embedded 4-μm-thick tumor sections were stained with rat anti-mouse CD34 (RAM 34, Pharmingen) and mouse anti-human smooth muscle actin (SMA; clone 1A4, DAKO) antibodies as previously described by Spurbeck et al. (25) . Stained tumor sections were viewed and digitally photographed using an Olympus U-SPT microscope equipped with both fluorescence and brightfield illumination with an attached CCD camera. Images were saved as JPEG files for further processing in Adobe Photoshop (Adobe Systems, Inc.). Four images at 400× were taken of each tumor section with care to avoid areas of necrosis. Positive staining was quantified using NIH image analysis software (Image J) and is reported as the mean number of positive pixels/ tumor section. Apoptosis in tumors was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling using a commercially available in situ apoptosis detection kit (Serologicals). Densities of apoptotic cells were determined by 400× light microscopy in the field with the highest density of apoptotic cells in a region that had no evidence of necrosis. Three highpower fields per tumor were counted with a minimum of 3,000 cells per tumor counted. The number of apoptotic cells per 1,000 cells was recorded.
Statistical Analyses
An approach based on isobolograms was used to assess the in vitro synergy between IFN-β and radiation (26, 27) . A weighed nonlinear dose-response model (27) using the SAS NLIN procedure was used to fit colony survival data. Observed three-dimensional dose-response plots, fitted dose-response plots, and isobolograms were generated. Dose-independent synergy of combined ionizing radiation and IFN-β was estimated from the model by the nonadditivity parameter, α, which indicates synergism (α > 0), antagonism (α < 0), or no interaction (α = 0). Additionally, data from cell lines indicating synergy by the α parameter were analyzed for dose-dependent synergy using Hewlett's joint potency ratio, R, with corresponding assessment of 10%, 50%, and 90% pharmacologic effect (28) . The pharmacologic effect was defined as 100 [(E max − E) / (E max − B)]%, wherein E max and B are model parameters for the maximal and minimal effects. E is the mean response, which is a function of doses, and makes the pharmacologic effect a function of doses as well.
All other results are reported as mean ± SEM. Increase in dB of contrast enhancement from baseline to peak perfusion was analyzed with Mann-Whitney U test in SAS statistical software. The Sigmaplot program (SPSS, Inc.) was used to analyze and graphically present all other data. An unpaired Student's t test was used to analyze statistical differences in the in vivo experimental results.
Results
Effect of Recombinant IFN-β on Alveolar Rhabdomyosarcoma Cells In vitro
Rh-41 and Rh-30 cells were analyzed for their sensitivity to IFN-β using an MTS viability assay (Fig. 1A) . Both lines were sensitive, although there were some differences observed in cell cycle and apoptotic response to IFN-β (Fig. 1B) . Rh-30, which exhibited greater sensitivity to IFN-β, showed a dramatic and highly significant increase in the percentage of cells in S phase at IFN-β concentrations at as low as 100 units/mL. However, no significant increase in apoptosis was observed in the Rh-30 cell line. Rh-41 cells, which were somewhat less sensitive to IFN-β, showed a modest yet statistically significant increase in the percentage of cells in S phase as well as a doubling of Annexin V-positive apoptotic cells when treated with concentrations of IFN-β at ≥100 units/mL.
Analysis of Synergism between IFN-β and Radiation Therapy in ARMS Cell Lines In vitro
Plotting the individual colony counts for each cell line after treatment provided a three-dimensional contour map of the response to treatment for that cell line with the Rh-30 cells producing more overall colonies ( Fig. 2A) . A weighed nonlinear dose-response model was fitted to each cell line (Fig. 2B ), and the model fit was highly significant for both cell lines (P < 0.001). IFN-β and ionizing radiation (X-ray therapy, XRT) showed synergy against the Rh-30 cell line, producing a positive α, nonadditivity, parameter of 1.34 [95% confidence interval (CI 95% CI), 0.70-1.98]. For treatment of the Rh-41 cells, however, the α parameter was 0.229 (95% CI, −0.078 to 0.537). Because the confidence interval included 0 in the Rh-41 cell line, we cannot definitely conclude that synergy between IFN-β and radiation therapy occurred in these cells; however, the effects were additive. Dose-dependent synergy was evaluated using Hewlett's joint potency ratios, R, corresponding to 10%, 50%, and 90% pharmacologic effects. R values in the Rh-30 model were 1.08, 1.26, and 1.71, thereby showing more synergy with higher dose combinations. The corresponding isobolograms for this model show bowing contours that give a visual indication of the degree of synergy (Fig. 2C) . Synergy was not observed between IFN-β and radiation in the Rh-41 cell line; however, additivity was seen and an isobologram was included to visually represent the additivity (Fig. 2C) . The Hewlett's joint potency ratios corresponding to 10%, 50%, and 90% pharmacologic effects were 1.01, 1.05, and 1.27 for the Rh-41 cell line.
Rhabdomyosarcoma Animal Model and Treatment Course
Orthotopic human Rh-30 ARMS tumors were established in the right calf muscles of CB17 severe combined A, sensitivity to IFN-β. Sensitivity to IFN-β was established in Rh-41 and Rh-30 cell lines using an MTS assay. Data are shown for 96 h treatments with 10 to 10,000 units of rhIFN-β. All measurements were done with 12 replicates. Points, mean; bars, SEM. B, alterations in cell cycle. Flow cytometry revealed that IFN-β causes S-phase arrest after 72 h of treatment (Rh-30, P < 0.002 for 100, 1,000, and 10,000 units/mL; Rh-41, P < 0.0001 for 10, 100, 1,000, and 10,000 units/mL). All measurements were done in triplicate. Columns, mean; bars, SEM. C, apoptosis in Rh-41 cells but not Rh-30 cells. Flow cytometry for Annexin V staining revealed that IFN-β causes apoptosis in Rh-41 cells (P < 0.01 for 100, 1,000, andimmunodeficient mice. These tumors mimicked ARMS behavior in humans with an infiltrative growth pattern (Fig. 3A) . After ∼3 weeks of growth, mice were size-matched by tumor volume into groups of eight mice each. One group served as an untreated control, one group was treated at 3 weeks of tumor growth with AAV-IFN-β (2.34 × 10 9 gc/mouse) only, one group received radiation treatment (4 Gy) only, and one group received AAV-IFN-β (2.34 × 10 9 gc) followed 1 week later by radiation treatment. Mice were sacrificed, and tissue was harvested 21 days after the initiation of treatment, which was the end point of the study. To evaluate the extent to which treatment efficacy was due to IFN-β-mediated vascular changes and sensitization of tumor cells before radiation or simply a combination of two treatment effects, an additional group was treated with radiation followed by AAV-IFN-β (2.34 × 10 9 gc) 1 week later. Human IFN-β was undetectable in the plasma of all untreated control mice and all mice were treated only with radiation, but mice treated with AAV-IFN-β had an average systemic level of human IFN-β of 335 ± 82 pg/mL 10 days after administration.
Maturation of the Tumor Vessels in IFN-β-Treated ARMS Xenografts
Twenty-one days after the initiation of treatment, five Rh-30 tumor-bearing mice per treatment group were euthanized and tumor tissue was harvested for staining. Immunohistochemical analysis was done to evaluate the effect of continuous IFN-β therapy on the tumor vasculature at the cellular level. As we have previously observed in neuroblastoma xenografts (11) , there was a Figure 2 . Evaluation of in vitro synergy between IFN-β and radiation in the treatment of alveolar rhabdomyosarcoma cell lines. A, observed three-dimensional colony survival surface. Actual colony survival data were averaged. B, predicted three-dimensional colony survival surface. Weighed nonlinear dose-response surface models of colony survival data for IFN-β plus ionizing radiation (XRT) in both cell lines were estimated from fitting the joint potency model equation. The model fit was good for both cell lines (P < 0.001). Dose-independent synergy of combined therapy was estimated from the model by the nonadditivity parameter, α, which indicates synergism (α > 0), antagonism (α < 0), or no interaction (α = 0). IFN-β and XRT showed synergy against the Rh-30 cell line, producing a positive α, nonadditivity parameter of 1.34 (95% CI, 0.70-1.98). The α parameter for Rh-41 cells was 0.229 (95% CI, −0.78 to 0.527), showing only additivity, not synergy, because the confidence interval included zero. C, isobolograms corresponding to 10% (large dashes), 50% (medium dashes), and 90% (small dashes) pharmacologic effect. Both cell lines were analyzed for dose-dependent synergy using Hewlett's joint potency ratio, R, with corresponding assessment of 10%, 50%, and 90% pharmacologic effect. R values for the Rh-30 model were 1.08, 1.26, and 1.71, indicating increased synergy with increasing dose combinations. R values for the Rh-41 model were 1.01, 1.05, and 1.27, indicating only additivity.
significant increase in the number of intratumoral vascular smooth muscle cells (VSMC), as identified by their positive α-SMA staining, with IFN-β treatment [24,873 ± 3,531 pixels/high power field (HPF)]. In contrast, the vessels in control tumors had much less VSMC investment (14,419 ± 2,095 pixels/HPF, P = 0.02; Fig. 3B ; representative α-SMA slides are shown in Fig. 3C and D) . Also previously observed in neuroblastoma xenografts (11) , there was a significant increase in the number of endothelial cells, as identified by CD34 staining, in the IFN-β-treated group (104,694 ± 33,145 pixels/HPF) compared with control tumors (15,976 ± 1,648 pixels/HPF, P = 0.02; Fig. 4 ). This increase in both endothelial cells and VSMCs suggests stabilization of tumor vasculature after treatment with IFN-β (representative CD34 slides of Rh-30 control and IFN-β-treated slides are shown in Fig. 4B and C) .
Decreased Interstitial Fluid Pressure in IFN-β-Treated ARMS Xenografts
The paucity of VSMCs in tumors is often associated with unstable, leaky vessels, which can result in increased edema within tumors. With increasing edema, there is increasing interstitial fluid pressure, which is thought to cause the collapse of smaller blood vessels, thereby hindering tumor perfusion. Interstitial fluid pressure (Fig. 5A ) measured 1 week after treatment in the Rh-30 tumors of mice treated with AAV-IFN-β (2.34 × 10 9 gc) was 3.1 ± 0.47 cm H 2 O, which was significantly lower than the interstitial pressure in the tumors of untreated mice (9.6 ± 2.7 cm H 2 O, P = 0.007). A dose-response relationship was observed as higher doses of AAV-IFN-β (4.66 × 10 10 gc) resulted in an even further decrease in interstitial pressure (0.1 ± 0.95 cm H 2 O, P = 0.011).
Improved Perfusion and Oxygenation in IFN-β-Treated ARMS Xenografts
We have previously shown that contrast-enhanced ultrasound can be used to evaluate changes in tumor perfusion (12) . Six days after the administration of ionizing radiation or AAV-IFN-β and one day before treatment with the second agent in the combination therapy groups, tumor perfusion was evaluated with contrast-enhanced ultrasound. The change in signal intensity from baseline to peak was 1.4 times greater in tumors treated with IFN-β (53.3 ± 4.9 dB) compared with untreated tumors (36.8 ± 4.6 dB, P = 0.023) in the Rh-30 tumors. The change in signal intensity for the Rh-41 tumors was 2.6 times higher in tumors treated with IFN-β (135.1 ± 28.5 dB) versus untreated tumors (52.8 ± 11.5 dB, P = 0.02; Fig. 5B ). These data suggest that tumors treated with IFN-β had significantly greater perfusion than control tumors in both tumor lines (representative contrast-enhanced images from IFN-β-treated and control mice are presented in Fig. 5C ). 9 gc) was 3.1 ± 0.47 cm H 2 O, which was significantly lower than the interstitial pressure in the tumors of untreated mice (9.6 ± 2.7 cm H 2 O; *, P = 0.007). Higher doses of AAV-IFN-β (4.66 × 10 10 gc) resulted in even further decrease in interstitial fluid pressure (0.1 ± 0.95 cm H 2 O; **, P = 0.011). B, perfusion shown by contrast-enhanced ultrasonography. The change in signal intensity from baseline to peak was 1.4 times greater in tumors treated with IFN-β (53.3 ± 4.9 dB) compared with untreated tumors (36.8 ± 4.6 dB;^, P = 0.02) in the Rh-30 tumors. The change in signal intensity for the Rh-41 tumors was 2.6 times higher in tumors treated with IFN-β (135.1 ± 28.5 dB) versus untreated tumors (52.8 ± 11.5 dB;^^, P = 0.02). C, representative control and IFN-β-treated contrast-enhanced ultrasound images. D, intratumoral oxygenation in Rh-30 and Rh-41 tumors. The partial pressure of oxygen in Rh-30 tumors treated with IFN-β (27.5 ± 4.3 mm Hg) was significantly higher than untreated tumors (0.6 ± 0.3 mm Hg; +, P < 0.001) or radiation-treated tumors (4.1 ± 2.9 mm Hg; ++, P = 0.001). Rh-41 tumors also had a significantly higher intratumoral oxygenation than controls (35.3 ± 13.4 mm Hg versus 3.3 ± 2.9 mm Hg; #, P < 0.05).
Given the improved tumor perfusion seen with IFN-β, we hypothesized that IFN-β-treated tumors would also have increased oxygenation; therefore, the following day tumors were tested with the OxyLab probe to determine intratumoral oxygen tension (Fig. 5D) . Using the Oxylab probe inserted directly in orthotopic tumors, we found that the partial pressure of oxygen in Rh-30 tumors treated with IFN-β (27.5 ± 4.3 mm Hg) was significantly higher than untreated tumors (0.6 ± 0.3 mm Hg, P < 0.001) or radiationtreated tumors (4.1 ± 2.9 mm Hg, P = 0.001). Rh-41 tumors also had a significantly higher intratumoral oxygenation than controls (35.3 ± 13.4 versus 3.3 ± 2.9 mm Hg, P < 0.05; Fig. 5D ).
AAV-IFN-β-Mediated Vascular Maturation Improves Tumor Response to Radiation
Whereas it may seem counterintuitive to view increased tumor oxygenation as a desired effect of a treatment, the important role of oxygen in effective radiation cell killing led us to propose that increased oxygenation would correlate with increased response to radiation. IM Rh-30 xenografts treated with continuous IFN-β alone showed slowed progression of tumor volume (Fig. 6A) , as did tumors treated with radiation alone. The greatest growth restriction, however, occurred in mice treated with combination therapy. Tumor volume with the combination therapy of AAV-IFN-β before radiation (605.9 ± 67.7 mm Fig. 6C ). Tumor volumes in mice treated with combination therapy were smaller than those mice treated with IFN-β alone (228.9 ± 43.8 mm 3 , P = 0.12), although the difference did not reach statistical significance.
To ensure that the AAV vector itself had no effect on tumor vascular phenotype or xenograft growth, mice with Rh-30 i.m. tumors were divided into two groups of five mice and received either no treatment or AAV-FIX (4.66 × 10 10 gc). The same methods described above were used to determine vascular smooth muscle investment, endothelial cell density, tumor perfusion, intratumoral oxygenation, and tumor volumes. . Finally, to determine whether pretreatment with IFN-β could lower the necessary dose of radiation required for tumor shrinkage, thereby, potentially limiting the toxicity of radiation therapy, increasing levels of radiation were given to additional cohorts (four mice per cohort) of size-matched Rh-30 tumors. At the highest single doses of radiation tested, tumors were still larger than when IFN-β was given before 4-Gy radiation (Fig. 6D) , showing that pretreatment with IFN-β lowered the dose of radiation necessary to achieve the same therapeutic effect of radiation alone by 75%; the mice treated with this combination showed no detectable signs of toxicity.
Discussion
Several investigators have found that type I IFNs sensitize various tumor cell lines to the cytotoxic effects of ionizing radiation (19, (29) (30) (31) . Our study shows that this also occurs in alveolar rhabdomyosarcoma cells. Our results also suggest an additional mechanism for the increased response to radiation following treatment with IFN-β in vivo. IFN-β-mediated changes in tumor vasculature seem to improve the perfusion and oxygenation of ARMS tumors, and this increased oxygenation was associated with an improved response to ionizing radiation.
Although new blood vessel formation occurs to support tumor growth, these vessels are generally very abnormal, with disorganized structure and function (32) (33) (34) . On a cellular level, there are often fewer stabilizing perivascular cells resulting in highly permeable vessels and increased intratumoral interstitial fluid pressure. These abnormal blood vessels provide inefficient perfusion of the tumor. Consequently, areas of tumor that are hypoxic, acidotic, and often necrotic develop. Drug delivery is poor and radiation is ineffective in the resultant tumor microenvironment, because these modalities require adequate tissue oxygenation, target cell proliferation, and, in the case of chemotherapy, local delivery to achieve maximal antitumor efficacy.
As early as the 1970s investigators showed that angiogenesis inhibitors could enhance the antitumor effect of other chemotherapeutic agents when given in conjunction with these agents, likely through improved perfusion of the tumor (35, 36) . "Normalization" of the tumor vasculature is a possible explanation for this paradoxical synergy between antiangiogenic drugs and cytotoxic agents (35) (36) (37) . We have previously shown that continuous delivery of IFN-β can effect normalization of the vasculature in neuroblastoma leading to improved antitumor effect when combined with traditional chemotherapeutic agents (11) . Treatment with IFN-β was associated with an increase in the number of stabilizing smooth muscle cells per endothelial cell, which fortified the tumor blood vessels and increased delivery of topotecan to the tumor. A similar increase in stabilizing smooth muscle cells was also seen when Rh-30 alveolar rhabdomyosarcoma xenografts were treated with IFN-β. IFN-β also decreased the interstitial fluid pressure within the tumor, likely through the process of vascular normalization. More stable, thicker-walled, less tortuous vessels would be expected to leak less fluid into the interstitial space. Decreased interstitial fluid pressure may allow better perfusion of the tumor especially through low pressure capillaries.
Whether secondary to decreased interstitial fluid pressure or another effect of vascular normalization, treatment with IFN-β was associated with increased perfusion of ARMS tumors, as indicated by increased contrast enhancement on ultrasound and better tumor oxygenation in both Rh-30 and Rh-41 tumors. This increased oxygenation is important for improving the effectiveness of radiation therapy, because ionizing radiation kills tumor cells through the generation of oxygen free radicals. Indeed, treatment with IFN-β was associated with increased tumor oxygen tension and increased tumor response to radiation in our study, even more so when IFN-β was given before ionizing radiation. This trend was also observed in the Rh-41 cell line with combined therapy having an additive effect, although it was not synergistic in vitro. This implies that in vivo there were changes effected by IFN-β that were independent of its direct effect on tumor cells, involving a more complex mechanism.
In conclusion, IFN-β was shown to have direct toxicity to alveolar rhabdomyosarcoma and sensitized cells of this histologic type to ionizing radiation in vitro. In vivo continuous IFN-β also seemed to effect maturation of tumor vasculature, which resulted in a decrease in interstitial fluid pressure while increasing the perfusion and oxygenation of rhabdomyosarcoma xenografts. This likely contributed to the improved tumor response to ionizing irradiation, although the timing of the administration of these two agents is important. Based on these results, IFN-β and radiation therapy may be effective in the clinical treatment of alveolar rhabdomyosarcoma.
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